Skip to main content

Clarification: Shareholder proposals for the 2014 Annual General Meeting in Enzymatica AB (publ)

Press Release   •   May 15, 2014 09:10 GMT

Information on the shareholders' voting power was not included in the press release at 8:30. Below is the information reported.

Shareholders representing about 13 percent of all shares and votes in the company have submitted the following draft resolutions for the AGM 2014:

The Chairman, Christian Westin Jansson shall be elected Chairman of the Meeting.

The number of Directors shall be five, but deputies.
Chairman of the Board: Re-election of Christian Westin Jansson Board of Directors: Re-election of the Board members Fredrik Lindberg, Jörgen Rexö and Anders Jungbeck. Election of Marianne Dicander Alexandersson.

Marianne Dicander Alexandersson, born in 1959 and MSc in Chemical Engineering from Chalmers University of Technology, Gothenburg. She has previous experience as Managing Director of Global Health Partner AB and the Sixth AP Fund, Deputy CEO of Apoteket AB, CEO of Crown Droghandel and experience in quality and market from various industries such as automotive, plastic and chemical industry, and pharmaceutical and healthcare logistics. She is a board member of Recipharm AB (publ), Director of Mölnlycke Health Care AB and other companies in the Mölnlycke Group, Member of the Board of Castellum AB, Director and Managing Director at MDA Management AB and a member of the Royal Swedish Academy of Engineering Sciences. Marianne Dicander Alexandersson holds no shares in Enzymatica.

Director remuneration: Excluding committee remuneration, a total of SEK 540 000, of which SEK 180,000 to the Chairman and SEK 120 000 to each of the other Board members who are not employees of the company. For work on the audit committee, the remuneration shall be 50 000 SEK to the Chairman and no compensation to the other members. For work in the remuneration committee no compensation will be paid.

This is a translation of the Swedish announcement. When in doubt, the Swedish wording prevails.

For more information, please contact:
Michael Edelborg Christensen, CEO Enzymatica AB (publ) Phone: +46 768 14 41 66. Mail: michael.christensen@enzymatica.se  


About Enzymatica AB (publ)
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical device products based on a patented enzyme technology. Enzymatica has several projects in the pipeline for diseases of the skin, throat and mucous membranes. Enzymatica has two registered medical device products, PeriZyme® Chewing Gum CE, against oral cavity diseases and ColdZyme® Mouth Spray CE against the common cold, the latter recently launched throughout the country.

About Enzymatica online
Enzymatica’s press room »
Enzymatica’s website »
Enzymatica on LinkedIn »
Enzymatica on twitter »
For Investors »
For Investors »
ColdZyme website »
ColdZyme on facebook »


Attached Files

PDF document

Comments (0)

Add comment

Comment